Isoptin: Advanced Calcium Channel Blockade for Cardiovascular Control
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.15 | $34.40 (0%) | 🛒 Add to cart |
| 60 | $0.82 | $68.80 $49.02 (29%) | 🛒 Add to cart |
| 90 | $0.72 | $103.20 $64.50 (38%) | 🛒 Add to cart |
| 120 | $0.67 | $137.60 $79.98 (42%) | 🛒 Add to cart |
| 180 | $0.61 | $206.40 $109.22 (47%) | 🛒 Add to cart |
| 270 | $0.57 | $309.60 $153.94 (50%) | 🛒 Add to cart |
| 360 | $0.55
Best per pill | $412.80 $199.52 (52%) | 🛒 Add to cart |
| Product dosage: 240mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.49 | $44.72 (0%) | 🛒 Add to cart |
| 60 | $1.12 | $89.44 $67.08 (25%) | 🛒 Add to cart |
| 90 | $1.00 | $134.16 $90.30 (33%) | 🛒 Add to cart |
| 120 | $0.93 | $178.88 $111.80 (38%) | 🛒 Add to cart |
| 180 | $0.87 | $268.32 $156.52 (42%) | 🛒 Add to cart |
| 270 | $0.83 | $402.48 $225.32 (44%) | 🛒 Add to cart |
| 360 | $0.81
Best per pill | $536.64 $290.68 (46%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.62 | $36.98 (0%) | 🛒 Add to cart |
| 90 | $0.51 | $55.47 $45.58 (18%) | 🛒 Add to cart |
| 120 | $0.44 | $73.96 $53.32 (28%) | 🛒 Add to cart |
| 180 | $0.39 | $110.94 $70.52 (36%) | 🛒 Add to cart |
| 270 | $0.35 | $166.41 $94.60 (43%) | 🛒 Add to cart |
| 360 | $0.33
Best per pill | $221.88 $119.54 (46%) | 🛒 Add to cart |
Isoptin (verapamil hydrochloride) represents a cornerstone in cardiovascular pharmacotherapy, offering targeted calcium channel blockade to manage hypertension, angina pectoris, and specific arrhythmias. As a class IV antiarrhythmic and antihypertensive agent, it exerts its effects through selective inhibition of calcium ion influx across cardiac and vascular smooth muscle cell membranes. This mechanism results in reduced peripheral vascular resistance, decreased myocardial oxygen demand, and modulation of cardiac conduction pathways. Clinicians value Isoptin for its well-established efficacy profile and predictable pharmacokinetics when administered according to evidence-based guidelines.
Features
- Contains verapamil hydrochloride as the active pharmaceutical ingredient
- Available in immediate-release (80mg, 120mg) and sustained-release formulations (120mg, 180mg, 240mg)
- Exhibits selective inhibition of L-type calcium channels
- Demonstrates high bioavailability and extensive hepatic metabolism
- Shows concentration-dependent effects on AV nodal conduction
- Provides dual action on both vascular smooth muscle and cardiac tissue
Benefits
- Effectively reduces elevated blood pressure through vasodilation and decreased peripheral resistance
- Decreases frequency and severity of angina episodes by reducing myocardial oxygen demand
- Controls supraventricular tachyarrhythmias through AV nodal conduction modulation
- Offers 24-hour blood pressure control with extended-release formulations
- Demonstrates renal protective effects in hypertensive patients
- Provides cardioprotective benefits beyond blood pressure reduction
Common use
Isoptin is primarily indicated for the management of essential hypertension, either as monotherapy or in combination with other antihypertensive agents. It is equally effective in treating chronic stable angina pectoris and vasospastic angina. The medication finds significant application in controlling supraventricular tachyarrhythmias, particularly for achieving ventricular rate control in atrial fibrillation and flutter. Off-label uses include migraine prophylaxis, hypertrophic cardiomyopathy management, and Raynaud’s phenomenon treatment. Clinical decision-making should always consider patient-specific factors including comorbidities, concomitant medications, and cardiovascular risk profile.
Dosage and direction
Dosage must be individualized based on clinical indication, patient response, and formulation type. For hypertension: Initial dose typically ranges from 80-120mg three times daily with immediate-release or 180-240mg once daily with sustained-release formulations. Maximum daily dose should not exceed 480mg. For angina: Starting dose is 80-120mg three times daily, titrated upward at weekly intervals. For arrhythmias: Digitalized patients with chronic atrial fibrillation may require 240-320mg daily in divided doses. Administration with food may minimize gastrointestinal discomfort. Tablets should be swallowed whole without crushing or chewing, particularly sustained-release formulations. Regular blood pressure monitoring and ECG assessment are recommended during dosage titration.
Precautions
Patients should be monitored for signs of heart failure, as verapamil possesses negative inotropic properties. Hepatic impairment requires dosage adjustment due to extensive first-pass metabolism. Renal function should be assessed periodically, particularly in elderly patients. Gradual withdrawal is recommended to avoid rebound hypertension or angina exacerbation. Patients with neuromuscular transmission disorders (such as Duchenne muscular dystrophy) require careful monitoring. Concomitant use with beta-blockers demands extreme caution due to potential additive effects on cardiac contractility and conduction. Regular laboratory monitoring including liver function tests is advised during long-term therapy.
Contraindications
Isoptin is contraindicated in patients with severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome, or second- or third-degree AV block without functioning pacemaker. Additional contraindications include hypotension (systolic pressure <90 mmHg), atrial flutter or fibrillation with accessory pathway (e.g., WPW syndrome), and known hypersensitivity to verapamil or any component of the formulation. The medication should not be administered concurrently with ivabradine due to risk of excessive bradycardia. Patients with severe hepatic impairment should not receive standard dosing regimens.
Possible side effect
Common adverse reactions include constipation (7-25%), dizziness (3-10%), nausea (2-7%), hypotension (2-5%), and peripheral edema (1-5%). Cardiovascular effects may include bradycardia, AV block, and heart failure exacerbation. Less frequent side effects encompass headache, fatigue, flushing, and rash. Serious but rare adverse events include hepatotoxicity, gingival hyperplasia, and parkinsonian symptoms. The incidence and severity of side effects often correlate with dosage and rate of titration. Most gastrointestinal and neurological side effects tend to diminish with continued therapy.
Drug interaction
Isoptin demonstrates significant interaction potential due to CYP3A4 metabolism and P-glycoprotein inhibition. Concurrent administration with beta-blockers may produce excessive bradycardia and heart block. Co-administration with digoxin increases digoxin serum concentrations by 50-75%. Statins metabolized by CYP3A4 (atorvastatin, simvastatin) may experience increased exposure. Interaction with cyclosporine can elevate cyclosporine levels by 2-3 fold. Concomitant use with disopyramide or flecainide within 48 hours may cause excessive myocardial depression. Erythromycin, clarithromycin, and antifungal azoles can significantly increase verapamil concentrations. Grapefruit juice should be avoided due to CYP3A4 inhibition.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In such cases, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never double the dose to compensate for a missed administration. For sustained-release formulations, consistency in dosing time is particularly important to maintain stable plasma concentrations. Healthcare providers should educate patients about the importance of adherence while providing clear guidance for occasional missed doses to prevent both under-treatment and potential toxicity from dose doubling.
Overdose
Verapamil overdose presents primarily with cardiovascular manifestations including severe hypotension, bradycardia, and conduction abnormalities. Additional symptoms may include confusion, nausea, and metabolic acidosis. Management requires immediate medical attention with continuous hemodynamic monitoring. Treatment includes gastric lavage if presentation is early, activated charcoal, and supportive care. Calcium gluconate (1g IV) may counteract cardiovascular effects. Inotropic support with dopamine or dobutamine may be necessary. Temporary pacing might be required for profound bradycardia or advanced heart block. Hemodialysis is not effective due to high protein binding and extensive tissue distribution.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) in original container protected from light and moisture. Keep tightly closed and away from excessive heat or humidity. Do not store in bathroom cabinets where moisture levels fluctuate. Keep all medications out of reach of children and pets. Do not use beyond the expiration date printed on packaging. Proper disposal of unused medication should follow local regulations, typically through medication take-back programs rather than flushing or household trash disposal.
Disclaimer
This information serves educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult qualified healthcare providers regarding medical conditions or before starting any new treatment. Individual patient responses may vary, and therapeutic decisions should be based on comprehensive clinical evaluation. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions. Healthcare professionals should reference complete prescribing information before administration.
Reviews
Clinical studies consistently demonstrate Isoptin’s efficacy in hypertension management with response rates exceeding 70% in stage 1-2 hypertension. Meta-analyses of angina trials show significant reduction in attack frequency and nitrate consumption. Cardiologists report particular satisfaction with its rhythm control properties in supraventricular tachyarrhythmias. Patient-reported outcomes indicate good tolerability profile, though constipation remains a frequently cited concern. Long-term observational studies confirm maintained efficacy with appropriate dose adjustment. The sustained-release formulation receives positive feedback for improved adherence compared to multiple daily dosing regimens.